<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0409245857
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SUMAREX 100 MG F.C.TABLET (2S)
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SUMATRIPTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        40.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N02CC01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each Sumarex&trade; film coated tablet contains a single dose of sumatriptan, which<br />belongs to a group of medicines called triptans (also known as 5-HT1 receptor<br />agonists).<br />Sumarex&trade; is used to treat migraine headache.<br />Migraine symptoms may be caused by the temporary widening of blood vessels in<br />the head. Sumarex&trade; is believed to reduce the widening of these blood vessels. This<br />in turn helps to take away the headache and relieve other symptoms of a migraine<br />attack, such as feeling or being sick (nausea or vomiting) and sensitivity to light and<br />sound.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Don&rsquo;t use Sumarex&trade;:<br />&bull; If you&rsquo;re allergic to sumatriptan, or any of the other ingredients of this medicine<br />(listed in section 6)<br />&bull; If you have a heart problem such as narrowing of the arteries (Ischaemic heart<br />disease) or chest pains (angina), or have already had a heart attack<br />&bull; If you have circulation problems in your legs that cause cramp-like pains when<br />you walk (peripheral vascular disease)<br />&bull; If you have had a stroke or a mini-stroke (also called a transient ischaemic attack<br />or TIA)<br />&bull; If you have high blood pressure. You may be able to use Sumarex&trade; if your high<br />blood pressure is mild and is being treated<br />&bull; If you have serious liver disease<br />&bull; With other migraine medicines, including those which contain ergotamine, or<br />similar medicines such as methysergide maleate; or any triptan or 5HT1 agonist<br />(such as naratriptan or zolmitriptan)<br />&bull; With any of the following anti-depressants:<br />- MAOIs (monoamine oxidase inhibitors) or if you have taken an MAOI in the last<br />2 weeks<br />- SSRIs (selective serotonin reuptake inhibitors) including citalopram, fluoxetine,<br />fluvoxamine, paroxetine and sertaline<br />- SNRIs (serotonin noradrenaline reuptake inhibitors) including venlafaxine and<br />duloxetine<br />&bull; For children under 18 years of age.<br />If any of these apply to you:<br />&bull; Tell your doctor, and don&rsquo;t use Sumarex&trade; tablets.<br />Take special care with Sumarex&trade;<br />Talk to your doctor or pharmacist before using Sumarex&trade;.<br />If you have any extra risk factors<br />&bull; If you are a heavy smoker, or using nicotine replacement therapy, and<br />especially<br />&bull; If you are a man aged over 40, or<br />&bull; If you are a woman who has been through the menopause.<br />In very rare cases, people have developed serious heart conditions after using<br />Sumarex&trade;, even though they had no signs of heart disease before. If any of the<br />points above applies to you it could mean you have a greater risk of developing heart<br />disease - so:<br />&bull; Tell your doctor so that your heart function can be checked before Sumarex&trade; is<br />prescribed for you.<br />If you have a history of fits (seizures)<br />Or if you have other conditions which might make it more likely that you&rsquo;ll have a fit<br />- for example, a head injury or alcoholism:<br />&bull; Tell your doctor so that you can be supervised more closely.<br />If you have had high blood pressure Sumarex&trade; may not be suitable for you<br />&bull; Tell your doctor or pharmacist before using Sumarex&trade;.<br />If you have liver or kidney disease<br />If either of these apply to you:<br />&bull; Tell your doctor or pharmacist before using Sumarex&trade;.<br />If you have an intolerance to some sugars<br />&bull; Tell your doctor so that you can be supervised more closely<br />If you are allergic to antibiotics called sulphonamides<br />If so, you may also be allergic to Sumarex&trade;. If you know you are allergic to an<br />antibiotic but you are not sure whether it is a sulphonamide:<br />&bull; Tell your doctor or pharmacist before using Sumarex&trade;.<br />If you are taking anti-depressants called SSRIs (Selective Serotonin Reuptake<br />Inhibitors) or SNRIs (Serotonin Noradrenaline Reuptake Inhibitors)<br />&bull; Tell your doctor or pharmacist before using Sumarex&trade;. Also see Other<br />medicines and Sumarex&trade;, below.<br />If you use Sumarex&trade; frequently.<br />Using Sumarex&trade; too often may make your headaches worse.<br />&bull; Tell your doctor if this applies to you. He or she may recommend you stop using<br />Sumarex&trade;.<br />If you feel pain or tightness in your chest after you use Sumarex&trade;<br />These effects may be intense but they usually pass quickly. If they don&rsquo;t pass<br />quickly, or they become severe:<br />&bull; Get medical help immediately. Section 4 (overleaf) has more information about<br />these possible side effects.<br />Other medicines and Sumarex&trade;<br />Tell your doctor or pharmacist if you&rsquo;re taking, have recently taken or might take<br />any other medicines. This includes any herbal products or medicines you&rsquo;ve bought<br />without a prescription.<br />Some medicines must not be taken with Sumarex&trade; and others may cause adverse<br />effects if they&rsquo;re taken with Sumarex&trade;. You must tell your doctor if you are<br />taking:<br />&bull; ergotamine also used to treat migraine, or similar medicines such as methysergide<br />(see section 2 Don&rsquo;t use Sumarex&trade;). Don&rsquo;t use Sumarex&trade; at the same time as these<br />medicines. Stop taking these medicines at least 24 hours before using Sumarex&trade;.<br />Don&rsquo;t take any medicines which contain ergotamine or compounds similar to<br />ergotamine again for at least 6 hours after using Sumarex&trade;.<br />&bull; other triptans/5-HT1 receptor agonists (such as naratriptan, rizatriptan,<br />zolmitriptan), also used to treat migraine, (see section 2 Don&rsquo;t use Sumarex&trade;).<br />Don&rsquo;t use Sumarex&trade; at the same time as these medicines. Stop taking these<br />medicines at least 24 hours before using Sumarex&trade;. Don&rsquo;t take another triptan/5-HT<br />1 receptor agonist again for at least 24 hours after using Sumarex&trade;.<br />&bull; MAOIs used to treat depression. Don&rsquo;t use Sumarex&trade; if you have taken these in<br />the last 2 weeks<br />&bull; SSRIs and SNRIs used to treat depression. Using Sumarex&trade; with these<br />medicines can cause serotonin syndrome (a collection of symptoms which can<br />include restlessness, confusion, sweating, hallucinations, increased reflexes, muscle<br />spasms, shivering, increased heartbeat and shaking). Tell your doctor immediately if<br />you are affected in this way.<br />&bull; St John&rsquo;s Wort (Hypericum perforatum). Taking herbal remedies that contain<br />St John&rsquo;s Wort together with Sumarex&trade; may make side effects more likely.<br />Pregnancy and breast-feeding<br />&bull; If you are pregnant, think you may be pregnant or are planning to have a<br />baby, ask your doctor for advice before taking this medicine. There is only limited<br />information about the safety of Sumarex&trade; for pregnant women, though up till now<br />there is no evidence of any increased risk of birth defects. Your doctor will discuss<br />with you whether or not you should use Sumarex&trade; while you are pregnant<br />&bull; Don&rsquo;t breast-feed your baby for 12 hours after using Sumarex&trade;. If you express<br />any breast milk during this time, discard the milk and don&rsquo;t give it to your baby.<br />Driving and using machines<br />Either the symptoms of migraine or your medicine may make you drowsy. If you are<br />affected, don&rsquo;t drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your<br />doctor or pharmacist if you are not sure.<br />When to take Sumarex&trade;<br />&bull; It&rsquo;s best to take Sumarex&trade; as soon as you feel a migraine coming on, although -<br />you can take it at any time during an attack<br />&bull; Don&rsquo;t use Sumarex&trade; to try to prevent an attack - only use it after your migraine<br />symptoms start.<br />How much to take<br />Adults aged 18 to 65<br />&bull; The usual dose for adults aged 18 to 65 is one Sumarex&trade; 50 mg tablet,<br />swallowed whole with water. Some patients may need a 100 mg dose - you should<br />follow your doctor&rsquo;s advice.<br />Children under 18<br />&bull; Sumarex&trade; is not recommended for children under 18 years old.</p><p>Elderly (aged over 65)<br />&bull; Sumarex&trade; is not recommended for people aged over 65.<br />If your symptoms start to come back<br />&bull; You can take a second Sumarex&trade; tablet if at least 2 hours have passed since the<br />first tablet. Don&rsquo;t take more than 300 mg in total in 24 hours.<br />If the first tablet has no effect<br />&bull; Don&rsquo;t take a second tablet or any other Sumarex&trade; preparation for the same attack.<br />Sumarex&trade; can still be used for your next attack.<br />If Sumarex&trade; doesn&rsquo;t give you any relief:<br />&bull; Ask your doctor or pharmacist for advice.<br />If you take more Sumarex&trade; than you should<br />&bull; Don&rsquo;t take more than six 50 mg tablets or three 100 mg tablets (300 mg in total)<br />in any 24 hours.<br />Taking too much Sumarex&trade; could make you ill. If you have taken more than 300 mg<br />in 24 hours:<br />&bull; Contact your doctor for advice.<br />If you have any further questions about the use of this medicine, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, but not everybody gets them.<br />Some symptoms may be caused by the migraine itself.<br />Allergic reaction: get doctor&rsquo;s help straight away<br />The following side effects have occurred but their exact frequency is not known.<br />&bull; The signs of allergy include rash, hives (itchy rash); wheezing; swollen eyelids,<br />face or lips; complete collapse.<br />If you get any of these symptoms soon after using Sumarex&trade;:<br />&bull; Don&rsquo;t use any more. Contact a doctor straight away.<br />Common side effects (affect up to 1 in 10 people)<br />&bull; Pain, heaviness, pressure or tightness in the chest, throat or other parts of the body,<br />or unusual sensations, including numbness, tingling and warmth or cold. These<br />effects may be intense but generally pass quickly.<br />If these effects continue or become severe (especially the chest pain):<br />&bull; Get medical help urgently. In a very small number of people these symptoms can<br />be caused by a heart attack.<br />Other common side effects include:<br />&bull; Feeling sick (nausea) or being sick (vomiting), although this may be due to the<br />migraine itself<br />&bull; Tiredness or drowsiness<br />&bull; Dizziness, feeling weak, or getting hot flushes<br />&bull; Temporary increase in blood pressure<br />&bull; Shortness of breath<br />&bull; Aching muscles.<br />Very rare side effects (affect up to 1 in 10,000 people)<br />&bull; Liver function changes. If you have a blood test to check your liver function, tell<br />your doctor or nurse that you are taking Sumarex&trade;.<br />Some patients may get the following side effects but it is not known how often<br />they occur<br />&bull; Seizures/fits, tremors, muscle spasm, neck stiffness<br />&bull; Visual disturbances such as flickering, reduced vision, double vision, loss of vision,<br />and in some cases even permanent defects (although these may be due to the migraine<br />attack itself)<br />&bull; Heart problems, where your heartbeat may go faster, slower or change rhythm, chest<br />pains (angina) or heart attack<br />&bull; Pale, blue-tinged skin and/or pain in your fingers, toes, ears, nose or jaw in response<br />to cold or stress (Raynaud&rsquo;s phenomenon)<br />&bull; Feeling faint (blood pressure may go down)<br />&bull; Pain in the lower left side of the stomach and bloody diarrhoea (ischaemic colitis)<br />&bull; Diarrhoea<br />&bull; Pain in the joints<br />&bull; Feeling anxious<br />&bull; Excessive sweating<br />Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any<br />possible side effects not listed in this leaflet.<br />By reporting side effects you can help provide more information on the safety of this<br />medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not use this medicine after the expiry date shown on the carton.<br />Do not store above 30 &deg;C.<br />Don&rsquo;t throw away any medicines via waste water or household waste. Ask your<br />pharmacist how to throw away medicines you no longer use. These measures will<br />help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Sumarex&trade; contains<br />&bull; The active substance is:<br />Sumarex&trade; 50mg: Each Film Coated Tablet contains 50 mg of Sumatriptan eq.to 70<br />mg of Sumatriptan Succinate.<br />Sumarex&trade; 100mg: Each Film Coated Tablet contains 100 mg of Sumatriptan eq.to<br />140 mg of Sumatriptan Succinate.<br />&bull; The other ingredients are:<br />Core: Lactose Monohydrate, Microcrystalline Cellulose, Croscarmellose Sodium,<br />Magnesium stearate.<br />Coating: Opadry White [Hydroxypropyl Methyl Cellulose, Titanium dioxide, Lactose<br />Monohydrate, Triacetin].</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Sumarex™ looks like and contents of the pack:
Sumarex™ 50mg are white, oval, biconvex, film coated tablets, engraved with 'JP
159' one side and plain on other side.
Sumarex™ 100mg are white, oval, biconvex, film coated tablets, engraved with 'JP
153' one side and plain on other side.
Sumarex™ 50mg film coated tablets are available in a blister pack containing 2
tablets or 6 tablets.
Sumarex™ 100mg film coated tablets are available in a blister pack containing 2
tablets or 6 tablets
Not all packs may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co.,<br />Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111,<br />Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                06/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><br />&trade; يحتوي كل قرص مغلف من سوماركس على جرعة واحدة من سوماتريبتان وهو دواء ينتمي لمجموعة<br />.(5-HT التريبتانات (المعروفة أيضًا باسم مناهضات مستقبلات 1<br />في علاج الصُّداع النصفي. &trade; يستخدم سوماركس<br />قد تكون أعراض الصداع النصفي ناجمة عن التوسع المؤقت للأوعية الدموية في الرأس. ويعتقد أن<br />يقلل من اتساع هذه الأوعية الدموية. مما يساعد بدوره في إزالة الصداع والأعراض &trade; سوماركس<br />الأخرى لنوبة الصداع النصفي مثل الشعور بالإعياء أو الإصابة به (الغثيان أو القيء) والحساسية تجاه<br />الصوت والضوء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>۲. ما الذي تحتاج إلى معرفته قبل استخدام سوماركس<br />في الحالات الآتية: &trade; لا تستخدم سوماركس<br />&bull; إذا كنت تعاني من حساسية تجاه سوماتريبتان أو أيٍّ من المكونات الأخرى الداخلة في تركيب هذا<br />.( الدواء (المدرجة في قسم ٦<br />&bull; إذا كنت تعاني من مشكلة في القلب مثل تضيق الشرايين (مرض القلب الإقفاري) أو آلام في الصدر<br />(الذبحة الصدرية) أو كان لديك بالفعل نوبة قلبية.<br />&bull; إذا كنت تعاني من مشاكل في الدورة الدموية في ساقيك تسبب آلامًا تشبه التشنج عند المشي (مرض<br />الاوعية الدموية المحيطية).<br />.(TIA &bull; إذا عانيت من سكتة دماغية أو سكتة دماغية صغرى (وتسمى أيضاً نوبة إقفارية مؤقتة أو<br />إذا كان ضغط الدم مرتفعاً &trade; &bull; إذا كنت تعاني من ارتفاع ضغط الدَّم. قد تتمكن من استخدام سوماركس<br />قليلاً ويتم علاجه.<br />&bull; إذا كنت مصاب بمرض كبدي خطير.<br />&bull; مع أدوية الصداع النصفي الأخرى بما في ذلك الأدوية التي تحتوي على الإرجوتامين أو أدوية مماثلة<br />.(5-HT مثل ميثيسيرجايد ماليت أو أي تريبتان أو مناهضات مستقبلات 1<br />&bull; مع أي من مضادات الاكتئاب التالية:<br />مثبطات أوكسيديز أحادي الأمين) أو إذا كنت قد أخذت مثبط أوكسيداز أحادي الأمين في ) MAOIs -<br />آخر أسبوعين<br />مثبطات استرداد السيروتونين الانتقائية) بما في ذلك سيتالوبرام وفلوكسيتين وفلوفوكسامين ) SSRIs -<br />وباروكسيتين وسيرترالين.<br />مثبطات استرداد السيتروتونين و النورأدرينالين) مثل فينلافاكسين ودولوكسيتين. ) SNRIs -<br />&bull; الأطفال أقل من ۱۸ عامًا<br />.&trade; - إذا انطبق عليك أيٌّ مما سبق، أخبر طبيبك المعالج ولا تتناول أقراص سوماركس<br />: &trade; توخ حذرًا خاصًّا مع سوماركس<br />.&trade; تحدث إلى طبيبك المعالج أو الصيدلي الخاص بك قبل استخدام سوماركس<br />إذا كان لديك أية عوامل خطورة إضافية<br />&bull; إذا كنت مدخنًا شرهاً أو تستخدم علاج بديل للنيكوتين ولا سيما<br />&bull; إذا كنت رجلاً يزيد عمره عن ٤۰ عامًا،<br />&bull; إذا كنتِ سيدة وصلت لسن انقطاع الطمث.<br />على الرغم من ،&trade; في حالات نادرة جدا، تعرض البعض لأمراض قلبية خطيرة بعد استخدام سوماركس<br />عدم وجود أعراض إصابة بأمراض القلب من قبل. إذا كانت أي من النقاط المذكورة أعلاه تنطبق عليك،<br />فقد يعني ذلك أن لديك قابلية أكثر للإصابة بأمراض القلب - لذلك:<br />لك. &trade; &bull; أخبر طبيبك المعالج لكي يفحص وظيفة القلب قبل أن يصف سوماركس<br />إذا كان لديك تاريخ مرضي من الإصابة بنوبات تشنج أو إذا كانت لديك حالات أخرى توحي بأنك<br />ستعاني من نوبة تشنج، على سبيل المثال إصابة في الرأس أو إدمان الكحول:<br />&bull; أخبر طبيبك المعالج بحيث يتابعك عن كثب.<br />مناسبًا لك. &trade; إذا كنت تعاني من ارتفاع ضغط الدم فقد لا يكون سوماركس<br />.&trade; &bull; أخبر طبيبك المعالج أو الصيدلي قبل استخدام سوماركس<br />إذا كنت تعاني من أمراض بالكبد أو بالكُلى إذا انطبق عليك أيٌّ مما سبق.<br />.&trade; &bull; أخبر طبيبك المعالج أو الصيدلي قبل استخدام سوماركس<br />إذا لم تكن قادرا على احتمال بعض أنواع السكر.<br />&bull; أخبر طبيبك المعالج بحيث يتابعك عن كثب.<br />إذا كنت تعاني من حساسية تجاه المضادات الحيوية التي تسمى السلفوناميدات.<br />إذا كنت تعرف أنك مصاب .&trade; إذا كان الأمر كذلك فقد يكون لديك أيضًا حساسية تجاه سوماركس<br />بالحساسية تجاه مضاد حيوي لكنك لست متأكداً ما إذا كان تجاه سلفوناميد أم لا:<br />.&trade; &bull; أخبر طبيبك المعالج أو الصيدلي قبل استخدام سوماركس<br />أو SSRIs إذا كنت تتناول مضادات الاكتئاب التي تسمى مثبطات استرداد السيروتونين الانتقائية<br />مثبطات إعادة امتصاص) السيتروتونين و ) SNRIs مثبطات إعادة امتصاص السيروتونين الانتقائية أو<br />النورأدرينالين)<br />انظر أيضًا قسم: أدوية أخرى و .&trade; &bull; أخبر طبيبك المعالج أو الصيدلي قبل استخدام سوماركس<br />أدناه. &trade; سوماركس<br />.&trade; إذا كنت تفرط في تناول سوماركس<br />في كثير من الأحيان إلى ازدياد الأمر (الصداع) سوءًا. &trade; قد يؤدي استخدام سوماركس<br />.&trade; &bull; أخبر طبيبك المعالج إذا كان هذا ينطبق عليك. قد يوصي الطبيب بوقف استخدام سوماركس<br />&trade; إذا شعرت بألم أو ضيق في صدرك بعد استخدام سوماركس<br />قد تكون هذه الآلام مبرحة ولكنها عادة ما تزول سريعاً. إذا لم تزل بسرعة أو أصبحت الألآم حادة:<br />&bull; أطلب المساعدة الطبية فورًا. يحتوي القسم ٤ (في الصفحة التالية) على مزيد من المعلومات حول هذه<br />الآثار الجانبية المحتملة.<br />&trade; تناول أدوية أخرى مع سوماركس<br />أخبر طبيبك المعالج أو الصيدلي الخاص بك إذا كنت تستعمل أية أدوية أخرى أو قد استعملتها مؤخرًا أو<br />قد تستعملها فيما بعد. وهذا يشمل أي أدوية عشبية أو أي أدوية قمت بشرائها بدون وصفة طبية.<br />و قد يسبب بعضها الآخر آثاراً عكسية إذا تم تناولها مع &trade; يجب عدم تناول بعض الأدوية مع سوماركس<br />.&trade; سوماركس<br />يجب إخبار طبيبك المعالج إذا كنت تستخدم:<br />&bull; إرجوتامين الذي يستخدم أيضًا في علاج الصداع النصفي أو أدوية مماثلة مثل ميثيسيرجايد (أنظر<br />في نفس الوقت مع هذه الأدوية. توقف عن &trade; لا تستخدم سوماركس .(&trade; القسم ۲ لا تستخدم سوماركس<br />لا تتناول أية أدوية تحتوي على .&trade; تناول هذه الأدوية قبل ۲٤ ساعة على الأقل من استخدام سوماركس<br />الإرجوتامين أو مركبات مماثلة للإرجوتامين مرة أخرى لمدة ٦ ساعات على الأقل بعد استخدام<br />.&trade; سوماركس<br />5- (مثل ناراتريبتان وريزاتريبتان وزولميتريبتان) HT &bull; التريبتانات الأخرى/ مناهضات مستقبلات 1<br />لا تستخدم .(&trade; التي تستخدم أيضًا في علاج الصداع النصفي (أنظر القسم ۲. لا تستخدم سوماركس<br />في نفس الوقت مع هذه الأدوية. توقف عن تناوُل هذه الأدوية قبل ۲٤ ساعة على الأقل من &trade; سوماركس<br />5- مرة أخرى لمدة ۲٤ HT لا تتناول التريبتانات الأخرى /مناهضات مستقبلات 1 .&trade; استخدام سوماركس<br />.&trade; ساعة على الأقل بعد استخدام سوماركس<br />إذا &trade; التي تستخدم لعلاج الاكتئاب. لا تستخدم سوماركس (MAOIs) &bull; مثبطات أوكسيديز أحادي الأمين<br />كنت قد أخذت مثبط أكسيديز أحادي الأمين في آخر أسبوعين.<br />(SNRIs) ومثبطات استرداد و النورأدرينالين (SSRIs) &bull; مثبطات استرداد السيروتونين الانتقائية<br />مع هذه الأدوية متلازمة السيروتونين (مجموعة من &trade; لعلاج الاكتئاب يمكن أن يسبب استخدام سوماركس<br />الأعراض التي يمكن أن تشمل التململ والارتباك والتعرق والهلوسة وارتفاع المنعكسات والتشنجات<br />العضلية والارتعاش وزيادة نبض القلب والارتجاف). أخبر طبيبك المعالج على الفور إذا أحسست بهذه<br />الأعراض.<br />&bull; عشبة سانت جونز (هايبيريكم بيرفراتم). قد تناول الأدوية العشبية التي تحتوي على عشبة سانت جونز<br />مزيداً من الآثار الجانبية &trade; مع سوماركس<br />الحمل والرضاعة الطبيعية<br />&bull; إذا كنتِ حاملًا أو مرضعًا أو تعتقدين أنكِ حامل أو تخططين لإنجاب طفل فاستشيري طبيبك قبل تناوُل<br />للنساء الحوامل رغم أنه لا يوجد &trade; هذا الدَّواء. لا توجد سوى معلومات محدودة حول سلامة سوماركس<br />حتى الآن أي دليل على أي خطر متزايد للعيوب الخلقية. سوف يناقش طبيبك المعالج معك ما إذا كان<br />أثناء الحمل أم لا. &trade; يجب عليك استخدام سوماركس<br />.&trade; &bull; لا تقومي بإرضاع طفلك لمدة ۱۲ ساعة بعد استخدام سوماركس<br />إذا كنت تعصرين حليب الثدي خلال هذا الوقت، فتخلصِي من الحليب ولا تعطيه لطفلك.<br />القيادة واستخدام الآلات<br />قد تجعلك أعراض الصداع النصفي أو أعراض دوائك تشعر بالنعاس. إذا عانيت من هذه الآثار فلا تقم<br />بالقيادة أو تشغيل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائمًا هذا الدَّواء تماماً حسب تعليمات طبيبك المعالج. يُرجى مراجعة طبيبك المعالج أو الصيدلي<br />الخاص بك إذا لم تكن متأكدًا من كيفية التناوُل.<br />&trade; متى تتناول سوماركس<br />بمجرد الشعور بالصداع النصفي، على الرغم من إمكانية تناوله &trade; &bull; من الأفضل أن تستخدم سوماركس<br />في أي وقت أثناء النوبة.<br />لمحاولة منع حدوث نوبة -استخدمه فقط بعد بدء أعراض الصداع النصفي. &trade; &bull; لا تستخدم سوماركس<br />ما هي الكمية التي يجب تناوُلها؟<br />البالغون الذين تتراوح أعمارهم بين ۱۸ و ٦٥ عاماً<br />&bull; الجرعة المعتادة للبالغين الذين تتراوح أعمارهم بين ۱۸ إلى ٦٥ عام هي قرص واحد من<br />٥۰ ملجم ويبلع كاملا مع الماء. قد يحتاج بعض المرضى إلى جرعة ۱۰۰ ملجم - يجب &trade; سوماركس<br />عليك اتباع نصيحة طبيبك المعالج.<br />الأطفال أقل من ۱۸ عام<br />للأطفال أقل من ۱۸ عام. &trade; &bull; لا يُوصى باستخدام سوماركس<br />( المرضى من كبار السن (أكبر من ٦٥<br />للأشخاص أكبر من ٦٥ عام. &trade; - لا يُوصى باستخدام سوماركس</p><p>إذا بدأت الأعراض في العودة<br />ثانياً إذا مرت ساعتان على الأقل من تناول أول قرص. لا تتناول &trade; &bull; يمكنك تناول قرص من سوماركس<br />جرعة أكثر من ۳۰۰ ملجم في المجموع خلال ۲٤ ساعة.<br />إذا لم يكن للقرص الأول أي تأثير<br />لنفس النوبة. لا يزال من الممكن استخدام &trade; &bull; لا تأخذ قرصاً ثانٍياُ أو أي مستحضر آخر من سوماركس<br />للنوبة التالية. &trade; سوماركس<br />:&trade; إذا لم يُجدِ استخدام سوماركس<br />&bull; استشر طبيبك المعالج أو الصيدلي الخاص بك.<br />&trade; إذا تناولت كمية أكثر مما ينبغي من سوماركس<br />&bull; لا تتناول أكثر من ستة أقراص ٥۰ ملجم أو ثلاثة أقراص ۱۰۰ ملجم ( ۳۰۰ ملجم في المجمل) خلال<br />أي ۲٤ ساعة.<br />قد يصيبك بالمرض. إذا تناولت جرعة أكثر من ۳۰۰ ملجم خلال ۲٤ &trade; تناول الكثير من سوماركس<br />ساعة:<br />&bull; يُرجى استشارة طبيبك المعالج.<br />إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، استشرطبيبك المعالج أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية لكن لا تحدث لدى الجميع. قد تكون بعض الأعراض<br />ناتجة عن الصداع النصفي نفسه.<br />تفاعلات حساسية: احصل على مساعدة الطبيب فوراً<br />حدثت الآثار الجانبية التالية ولكن معدل تكرارها غير معروف.<br />- تشمل علامات الحساسية طفح جلدي وبثور (طفح جلدي وحكة) وضيق التنفس وتورم الجفون أو<br />الوجه أو الشفتين. إعياء كلي.<br />لا تستخدمه مجدداً. اتصل بطبيب &bull; .&trade; إذا أُصِبت بأيٍّ من هذه الأعراض مباشرة بعد تناول سوماركس<br />على الفور.<br />الآثار الجانبية الشائعة (تؤثر على ما يصل إلى ۱مريض من بين كل ۱۰ مرضي)<br />- ألم وثقل وضغط وضيق في الصدر والحلق أو أجزاء أخرى من الجسم، أو أحساس غير معتاد بما في<br />ذلك التنميل والوخز والسخونة أو البرد. قد تكون هذه الآلام حادة ولكنها عادة ما تزول سريعاً.<br />إذا استمرت هذه الآثار أو أصبحت شديدة (خاصة ألم الصدر):<br />&bull; أطلب المساعدة الطبية فورًا. يمكن أن تُسبب هذه الأعراض نوبة قلبية في عدد قليل جدا من المرضى.<br />تشمل الآثار الجانبية الشائعة الأخرى:<br />&bull; شعور بالإعياء (الإحساس بالغثيان) أو الإعياء (قيء) على الرغم من أن هذا قد يكون بسبب الصداع<br />النصفي نفسه.<br />&bull; إرهاق أو نعاس<br />&bull; دوخة وشعور بالضعف والإصابة بنوبات حرارة<br />&bull; ارتفاع مؤقت في ضغط الدم<br />&bull; ضيق في التَّنفس<br />&bull; آلام العضلات<br />آثار جانبية نادرة جداً<br />تُؤثر على ما يصل إلى ۱مريض من بين كل ۱۰,۰۰۰ مريض<br />- تغيرات في وظائف الكبد.<br />إذا كان تخضع فحص دم لمعرفة وظائف الكبد فأخبر طبيبك المعالج أو الصيدلي الخاص بك أنك تستخدم<br />.&trade; سوماركس<br />قد يعاني بعض المرضى من الآثار الجانبية التالية ولكن من غير المعروف معدل تكرار حدوثها<br />- نوبات تشنج ورعشة وتشنجات عضلية وتصلب الرقبة<br />- اضطرابات بصرية مثل وميض وانخفاض الرؤية وازدواج الرؤية وفقدان البصر، وفي بعض الحالات<br />حتى الضعف الدائم (على الرغم من أن هذا قد يكون ناجماً عن نوبة الصداع النصفي نفسها)<br />- مشاكل في القلب حيث قد تسير دقات قلبك بشكل أسرع أو أبطأ أو تغير إيقاع النبض وآلام الصدر<br />(الذبحة الصدرية) أو نوبة قلبية<br />- شحوب وتصبغ الجلد باللون الأزرق و / أو ألم في أصابع اليدين والقدمين وألم في الأذنين والأنف أو<br />ألم في الفك نتيجةً للبرد أو الإجهاد (ظاهِرَة رينود)<br />- شعور بالإغماء (قد ينخفض ضغط الدَّم)<br />- ألم في الجانب الأيسر السفلي من المعدة والإسهال الدموي (التهاب القولون الإقفاري)<br />- إسهال<br />- ألم في المفاصل.<br />- شعور بالقلق.<br />- تعرق شديد.<br />الإبلاغ عن الآثار الجانبية<br />إذا أُصبت بأية آثار جانبية، استشر طبيبك المعالج أو الصيدلي الخاص بك أو الممرض(ة) المتابع(ة) لك.<br />وتشمل: أية آثار جانبية مُحتمَلة غير المُدرجة في هذه النشرة.<br />من خلال إبلاغك عن الآثار الجانبية يمكنك المساعدة في توفير معلومات أكثر حول أمان استخدام هذا<br />الدَّواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ بعيدًا عن متناول و مرأى الأطفال.<br />لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العبوة الكرتونيَّة.<br />يحفظ في درجة حرارة لا تزيد عن ۳۰ درجة مئوية.<br />لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي<br />الخاص بك عن كيفية التَّخلص من الأدوية التي لم تعد تستخدمها. تُساعد هذه الإجراءات في الحفاظ على<br />البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>على ماذا يحتوي سوماركس<br />&bull; المادة الفعالة هي:<br />٥۰ ملجم: يحتوي كل قرص مغلف على ٥۰ ملجم من سوماتريبتان المكافئ ل ۷۰ ملجم من &trade; سوماركس<br />سوماتريبتان سكسينات.<br />۱۰۰ ملجم: يحتوي كل قرص مغلف على ۱۰۰ ملجم من سوماتريبتان المكافئ ل ۱٤۰ &trade; سوماركس<br />ملجم من سوماتريبتان سكسينات.<br />&bull; المكونات الأخرى هي:<br />قلب القرص: لاكتوز أحادي الهيدرات سليلوز دقيق التبلور وكروس كارميلوز الصوديوم وستيرات<br />الماغنسيوم.<br />الغلاف الخارجي: أوبادري أبيض (هيدروكسي بروبيل ميثيل السليلوز وثاني أكسيد التيتانيوم ولاكتوز<br />أحادي الهيدرات وثُلاثي الأَستين)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>وما هي محتويات العبوة؟ ؟ &trade; ما هو شكل سوماركس<br />على (JP ٥۰ ملجم أقراص لونها أبيض ، بيضاوية ، ثنائية التحدب ، مغلفة ، محفور ( 159 &trade; سوماركس<br />جانب واحد و مستوية على الجانب الآخر.<br />على (JP ۱۰۰ ملجم أقراص لونها أبيض ، بيضاوية ، ثنائية التحدب ، مغلفة ، محفور( 153 &trade; سوماركس<br />جانب واحد و مستوية على الجانب الآخر.<br />٥۰ ملجم أقراص مغلفة تتوفر في عبوة بها تحتوى على ۲ قرص أو ٦ أقراص. &trade; سوماركس<br />۱۰۰ ملجم أقراص مغلفة تتوفر في عبوة بها تحتوى على ۲ قرص أو ٦ أقراص.&trade; سوماركس</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><img src="data:image/png;base64,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" /></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            06/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sumarex™ 100 mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated tablet contains
100mg sumatriptan (as the succinate).
For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                100 mg Sumatriptan description:
Commercial: White, oval, biconvex film coated tablets engraved with 'JP153' on one side and plain on
the other side.
Exhibit: White, oval, biconvex film coated tablets engraved with 'JP96' on one side and plain on the
other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sumarex&trade; Film Coated Tablets are indicated for the acute relief of migraine attacks, with or without aura.<br />Sumarex&trade; should only be used where there is a clear diagnosis of migraine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Adults<br />Sumatriptan film-coated tablets are indicated for the acute intermittent treatment of migraine. They<br />should not be used prophylactically.</p><p>It is advisable that Sumatriptan film-coated tablets be given as early as possible after the onset of<br />migraine attack but it is equally effective at whatever stage of the attack it is administered.<br />The recommended dose of oral Sumatriptan film-coated tablets is a single 50 mg tablet. Some patients<br />may require 100 mg. If the patient has responded to the first dose but the symptoms recur a second dose<br />may be given in the next 24 hours provided that there is a minimum interval of two hours between the<br />two doses. No more than 300 mg should be taken in any 24 hour period.<br />Patients who do not respond to the prescribed dose of Sumatriptan film-coated tablets should not take a<br />second dose for the same attack. In these cases the attack can be treated with paracetamol,<br />acetylsalicylic acid, or non-steroidal anti-inflammatory drugs. Sumatriptan film-coated tablets may be<br />taken for subsequent attacks.<br />Sumatriptan film-coated tablets is recommended as monotherapy for the acute treatment of migraine<br />and should not be given concomitantly with ergotamine or derivatives of ergotamine (including<br />methysergide) (see section 4.3).<br />Paediatric population<br />The efficacy and safety of Sumatriptan film-coated tablets in children aged less than 10 years have not<br />been established. No clinical data are available in this age group.<br />The efficacy and safety of Sumatriptan film-coated tablets in children 10 to 17 years of age have not<br />been demonstrated in the clinical trials performed in this age group. Therefore the use of Sumatriptan<br />film-coated tablets in children 10 to 17 years of age is not recommended (see section 5.1).<br />Elderly (Over 65 years of age)<br />Experience of the use of Sumatriptan film-coated tablets in patients aged over 65 years is limited. The<br />pharmacokinetics do not differ significantly from a younger population but until further clinical data<br />are available, the use of Sumatriptan film-coated tablets in patients aged over 65 years is not<br />recommended.<br />Method of administration<br />The tablets should be swallowed whole with water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Sumatriptan should not be given to patients who have had myocardial infarction or have ischaemic
heart disease, coronary vasospasm (Prinzmetal's angina), peripheral vascular disease or patients who
have symptoms or signs consistent with ischaemic heart disease.
Sumatriptan should not be administered to patients with a history of cerebrovascular accident (CVA) or
transient ischaemic attack (TIA).
Sumatriptan should not be administered to patients with severe hepatic impairment.
The use of sumatriptan in patients with moderate and severe hypertension and mild uncontrolled
hypertension is contraindicated.
The concomitant administration of ergotamine or derivatives of ergotamine (including methysergide) or
any triptan/5-hydroxytryptamine1 (5-HT1) receptor agonist with sumatriptan is contraindicated (see
section 4.5).
Concurrent administration of monoamine oxidase inhibitors and sumatriptan is contraindicated.
Sumatriptan film-coated tablets must not be used within two weeks of discontinuation of therapy with
monoamine oxidase inhibitors.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sumatriptan film-coated tablets should only be used where there is a clear diagnosis of migraine.<br />Sumatriptan is not indicated for use in the management of hemiplegic, basilar or ophthalmoplegic<br />migraine.<br />The recommended doses of sumatriptan should not be exceeded. As with other migraine therapies,<br />before treating headaches in patients not previously diagnosed as migraineurs, and in migraineurs who<br />present atypical symptoms, care should be taken to exclude other potentially serious neurological<br />conditions.<br />It should be noted that migraineurs may be at risk of certain cerebrovascular events (e.g.<br />cerebrovascular accident, transient ischaemic attack).<br />Following administration, sumatriptan can be associated with transient symptoms including chest pain<br />and tightness which may be intense and involve the throat (see section 4.8). Where such symptoms are<br />thought to indicate ischaemic heart disease, no further doses of sumatriptan should be given and<br />appropriate evaluation should be carried out.<br />Sumatriptan should not be given to patients with risk factors for ischaemic heart disease, including<br />those patients who are heavy smokers or users of nicotine substitution therapies, without prior<br />cardiovascular evaluation (see section 4.3). Special consideration should be given to postmenopausal<br />women and males over 40 with these risk factors. These evaluations however, may not identify every<br />patient who has cardiac disease and, in very rare cases, serious cardiac events have occurred in patients<br />without underlying cardiovascular disease.<br />Sumatriptan should be administered with caution to patients with mild controlled hypertension, since<br />transient increases in blood pressure and peripheral vascular resistance have been observed in a small<br />proportion of patients (see section 4.3).<br />There have been rare post-marketing reports describing patients with serotonin syndrome (including<br />altered mental status, autonomic instability and neuromuscular abnormalities) following the use of a<br />selective serotonin reuptake inhibitor (SSRI) and sumatriptan. Serotonin syndrome has been reported<br />following concomitant treatment with triptans and serotonin noradrenaline reuptake inhibitors (SNRIs).<br />If concomitant treatment with sumatriptan and an SSRI/SNRI is clinically warranted, appropriate<br />observation of the patient is advised (see section 4.5).<br />Sumatriptan should be administered with caution to patients with conditions which may affect<br />significantly the absorption, metabolism or excretion of drugs, e.g. impaired hepatic or renal function.<br />A 50mg dose should be considered in patients with hepatic impairment.</p><p>Sumatriptan should be used with caution in patients with a history of seizures or other risk factors<br />which lower the seizure threshold, as seizures have been reported in association with sumatriptan (see<br />section 4.8).<br />Patients with known hypersensitivity to sulphonamides may exhibit an allergic reaction following<br />administration of sumatriptan. Reactions may range from cutaneous hypersensitivity to anaphylaxis.<br />Evidence of cross-sensitivity is limited, however, caution should be exercised before using sumatriptan<br />in these patients<br />Undesirable effects may be more common during concomitant use of triptans and herbal preparations<br />containing St John&#39;s Wort (Hypericum perforatum).<br />Prolonged use of any type of painkiller for headaches can make them worse. If this situation is<br />experienced or suspected, medical advice should be obtained and treatment should be discontinued.<br />The diagnosis of medication overuse headache (MOH) should be suspected in patients who have<br />frequent or daily headaches despite (or because of) the regular use of headache medications.<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose<br />malabsorption should not take this medicine as it contains lactose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies in healthy subjects show that sumatriptan does not interact with propranolol, flunarizine,<br />pizotifen or alcohol. There are limited data on an interaction with preparations containing ergotamine<br />or another triptan/5-HT1 receptor agonist. The increased risk of coronary vasospasm is a theoretical<br />possibility and concomitant administration is contraindicated (see section 4.3).<br />The period of time that should elapse between the use of sumatriptan and ergotamine-containing<br />preparations or another triptan/5-HT1 receptor agonist is not known. This will also depend on the doses<br />and types of products used. The effects may be additive. It is advised to wait at least 24 hours following<br />the use of ergotamine-containing preparations or another triptan/5-HT1 receptor agonist before<br />administering sumatriptan. Conversely, it is advised to wait at least 6 hours following use of<br />sumatriptan before administering an ergotamine-containing product and at least 24 hours before<br />administering another triptan/5-HT1 receptor agonist.<br />An interaction may occur between sumatriptan and monoamine oxidase inhibitors (MAOIs) and<br />concomitant administration is contraindicated (see section 4.3).<br />There have been rare post-marketing reports describing patients with serotonin syndrome (including<br />altered mental status, autonomic instability and neuromuscular abnormalities) following the use of<br />SSRIs and sumatriptan. Serotonin syndrome has also been reported following concomitant treatment<br />with triptans and SNRIs (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy : Post-marketing data from the use of sumatriptan during the first trimester in over 1,000<br />women are available. Although these data contain insufficient information to draw definitive&nbsp;conclusions, they do not point to an increased risk of congenital defects. Experience with the use of<br />sumatriptan in the second and third trimester is limited.<br />Evaluation of experimental animal studies does not indicate direct teratogenic effects or harmful effects<br />on peri- and postnatal development. However, embryofoetal viability might be affected in the rabbit<br />(see section 5.3).<br />Administration of sumatriptan should only be considered if the expected benefit to the mother is greater<br />than any possible risk to the foetus.<br />Breastfeeding<br />It has been demonstrated that following subcutaneous administration sumatriptan is excreted into breast<br />milk. Infant exposure can be minimised by avoiding breast feeding for 12 hours after treatment, during<br />which time any breast milk expressed should be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Drowsiness<br />may occur as a result of migraine or treatment with sumatriptan. This may influence the ability to drive<br />and to operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse events are listed below by system organ class and frequency [4]. Frequencies are defined as:<br />very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1000 to &lt;1/100), rare (&ge;1/10,000<br />to &lt;1/1000), very rare (&lt;1/10000), not known (cannot be estimated from the available data). Some of<br />the symptoms reported as undesirable effects may be associated symptoms of migraine.<br />Clinical Trial Data<br />Nervous System Disorders<br />Common: Dizziness, drowsiness, sensory disturbance including paraesthesia and<br />hypoaesthesia.<br />Vascular Disorders<br />Common: Transient increases in blood pressure arising soon after treatment. Flushing.<br />Respiratory, Thoracic and Mediastinal Disorders<br />Common Dyspnoea.</p><p>Gastrointestinal Disorders<br />Common: Nausea and vomiting occurred in some patients but it is unclear if this is<br />related to sumatriptan or the underlying condition.<br />Musculoskeletal and Connective Tissue Disorders<br />Common: Sensations of heaviness (usually transient and may be intense and can affect<br />any part of the body including the chest and throat).<br />Myalgia.<br />General Disorders and Administration Site Conditions<br />Common: Pain, sensations of heat or cold, pressure or tightness (these events are<br />usually transient and may be intense and can affect any part of the body<br />including the chest and throat).<br />Feelings of weakness, fatigue (both events are mostly mild to moderate in<br />intensity and transient).<br />Investigations<br />Very rare: Minor disturbances in liver function tests have occasionally been observed.<br />Post-Marketing Data<br />Immune System Disorders<br />Not known: Hypersensitivity reactions ranging from cutaneous hypersensitivity to<br />anaphylaxis.<br />Nervous System Disorders<br />Not known: Seizures, although some have occurred in patients with either a history of<br />seizures or concurrent conditions predisposing to seizures there are also<br />reports in patients where no such predisposing factors are apparent.<br />Tremor, dystonia, nystagmus, scotoma.<br />Eye Disorders<br />Not known: Flickering, diplopia, reduced vision. Loss of vision including reports of<br />permanent defects. However, visual disorders may also occur during a<br />migraine attack itself.</p><p>Cardiac Disorders<br />Not known: Bradycardia, tachycardia, palpitations, cardiac arrhythmias, transient<br />ischaemic ECG changes, coronary artery vasospasm, angina, myocardial<br />infarction (see sections 4.3 and 4.4).<br />Vascular Disorders<br />Not known: Hypotension, Raynaud&#39;s phenomenon.<br />Gastrointestinal Disorders<br />Not known: Ischaemic colitis<br />Diarrhoea.<br />Musculoskeletal, Connective Tissue and Bone Disorders<br />Not known: Neck stiffness.<br />Arthralgia.<br />Psychiatric disorders<br />Not known: Anxiety.<br />Skin and subcutaneous tissue disorders<br />Not known: Hyperhidrosis.<br />To reports any side effect(s):<br />&bull; Saudi Arabia<br />-The National Pharmacovigilance and Drug Safety Centre (NPC) Fax: +966-<br />11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340. Toll free<br />phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doses in excess of 400mg orally were not associated with side effects other than those mentioned.<br />If overdosage occurs, the patient should be monitored for at least ten hours and standard supportive<br />treatment applied as required.<br />It is unknown what effect haemodialysis or peritoneal dialysis has on the plasma concentrations of<br />Sumarex.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Analgesics: Selective 5-HT1 receptor agonists.<br />ATC code: N02CC01<br />Sumatriptan has been demonstrated to be a specific and selective 5-Hydroxytryptamine1 (5HT1D)<br />receptor agonist with no effect on other 5HT receptor (5-HT2-5-HT7) subtypes. The vascular 5-<br />HT1D receptor is found predominantly in cranial blood vessels and mediates vasoconstriction. In<br />animals, sumatriptan selectively constricts the carotid arterial circulation but does not alter cerebral<br />blood flow. The carotid arterial circulation supplies blood to the extracranial and intracranial tissues<br />such as the meninges and dilatation of and/or oedema formation in these vessels is thought to be the<br />underlying mechanism of migraine in man.<br />In addition, evidence from animal studies suggests that sumatriptan inhibits trigeminal nerve activity.<br />Both these actions (cranial vasoconstriction and inhibition of trigeminal nerve activity) may<br />contribute to the anti-migraine action of sumatriptan in humans.<br />Sumatriptan remains effective in treating menstrual migraine i.e. migraine without aura that occurs<br />between 3 days prior and up to 5 days post onset of menstruation. Sumatriptan should be taken as<br />soon as possible in an attack.<br />Clinical response begins around 30 minutes following a 100mg oral dose.<br />Although the recommended dose of oral sumatriptan is 50mg, migraine attacks vary in severity both<br />within and between patients. Doses of 25-100mg have shown greater efficacy than placebo in clinical<br />trials, but 25mg is statistically significantly less effective than 50 and 100mg.</p><p>A number of placebo-controlled clinical studies assessed the safety and efficacy of oral sumatriptan<br />standard tablets in over 650 child and adolescent migraineurs aged 10 - 17 years. These studies failed<br />to demonstrate a statistically significant difference in headache relief at 2 hours between placebo and<br />any sumatriptan dose. The undesirable effects profile of oral sumatriptan in children and adolescents<br />aged 10 - 17 years was similar to that reported from studies in the adult population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following oral administration, sumatriptan is rapidly absorbed, 70% of maximum concentration<br />occurring at 45 minutes. After 100mg dose, the maximum plasma concentration is 54ng/ml. Mean<br />absolute oral bioavailability is 14% partly due to presystemic metabolism and partly due to incomplete<br />absorption. The elimination phase half-life is approximately 2 hours, although there is an indication of<br />a longer terminal phase. Plasma protein binding is low (14-21%), mean volume of distribution is 170<br />litres. Mean total plasma clearance is approximately 1160ml/min and the mean renal plasma clearance<br />is approximately 260ml/min. Non-renal clearance accounts for about 80% of the total clearance.<br />Sumatriptan is eliminated primarily by oxidative metabolism mediated by monoamine oxidase A.<br />Special patient populations<br />Hepatic Impairment<br />Sumatriptan pharmacokinetics after an oral dose (50 mg) and a subcutaneous dose (6 mg) were studied<br />in 8 patients with mild to moderate hepatic impairment matched for sex, age, and weight with 8<br />healthy subjects. Following an oral dose, sumatriptan plasma exposure (AUC and Cmax) almost<br />doubled (increased approximately 80%) in patients with mild to moderate hepatic impairment<br />compared to the control subjects with normal hepatic function. There was no difference between the<br />patients with hepatic impairment and control subjects after the s.c. dose. This indicates that mild to<br />moderate hepatic impairment reduces presystemic clearance and increases the bioavailability and<br />exposure to sumatriptan compared to healthy subjects.<br />Following oral administration, pre-systemic clearance is reduced in patients with mild to moderate<br />hepatic impairment and systemic exposure is almost doubled.<br />The pharmacokinetics in patients with severe hepatic impairment have not been studied (see Section<br />4.3 Contraindications and Section 4.4 Warnings and Precautions).<br />The major metabolite, the indole acetic acid analogue of Sumatriptan is mainly excreted in the urine,<br />where it is present as a free acid and the glucuronide conjugate. It has no known 5HT1 or&nbsp;5HT2 activity. Minor metabolites have not been identified. The pharmacokinetics of oral Sumatriptan<br />do not appear to be significantly affected by migraine attacks.<br />In a pilot study, no significant differences were found in the pharmacokinetic parameters between the<br />elderly and young healthy volunteers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sumatriptan was devoid of genotoxic and carcinogenic activity in in-vitro systems and animal studies.<br />In a rat fertility study oral doses of sumatriptan resulting in plasma levels approximately 200 times<br />those seen in man after a 100 mg oral dose were associated with a reduction in the success of<br />insemination.<br />This effect did not occur during a subcutaneous study where maximum plasma levels achieved<br />approximately 150 times those in man by the oral route.<br />In rabbits embryolethality, without marked teratogenic defects, was seen. The relevance for humans of<br />these findings is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The other ingredients are:<br /> Lactose Monohydrate<br /> Microcrystalline Cellulose Type PH102<br /> Croscarmellose Sodium<br /> Magnesium Stearate<br /> Opadry II White -32K280000<br /> Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C.<br />Keep out of reach and sight of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immediate Container: Alu-Alu Blister pack<br />Secondary Container: Carton &amp; PIL</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
P.O Box 6267,
Industrial Area, Phase V, Plot no.ME 1:3,
Jeddah, Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>